Aggregator
Frailty integration in medical specialties: Current evidence and suggested strategies from the Clin-STAR frailty interest group
Frailty is a syndrome that can inform clinical treatments and interventions for older adults. Although implementation of frailty across medical subspecialties has the potential to improve care for the aging population, its uptake has been heterogenous. While frailty assessment is highly integrated into certain medical subspecialties, other subspecialties have only recently begun to consider frailty in the context of patient care. In order to advance the field of frailty-informed care, we aim to...
Daily briefing: ‘We mourned together every day’: life at the heart of an outbreak
The cells that help the immune system fight lung cancer
Author Correction: Enhanced silica export in a future ocean triggers global diatom decline
Opponent control of reinforcement by striatal dopamine and serotonin
A mortality timer based on nucleolar size triggers nucleolar integrity loss and catastrophic genomic instability
Comprehensive single-cell aging atlas of healthy mammary tissues reveals shared epigenomic and transcriptomic signatures of aging and cancer
Forty years of crazy crystals
How the invasion of Ukraine is affecting Russian expat researchers
Why tumour geography matters — and how to map it
Turning a scientific lens on the wonderful world of fungi
Is the COP29 climate deal a historic breakthrough or letdown? Researchers react
Hopes, fears and uncertainty: life scientists react to Trump’s election victory
I defend the planet from asteroid collisions
I fled the war in Ukraine. Now I work on ways to help the country’s soil heal
Controversial Alzheimer’s drug from Cassava Sciences fails clinical testing
Beset by fraud allegations and government probes, Cassava pulls plug on all ongoing studies of simufilam
Producing circuit boards from leaves would prevent millions of tons of e-waste
Scientists take inspiration from trees to make electronics greener
<cite>Science</cite>’s ‘Dance Your Ph.D.’ contest is open again!
This year’s competition has a special category on artificial intelligence research or quantum science—no Ph.D. needed
‘Dark proteome’ survey reveals thousands of new human genes
Database confirms that overlooked segments of the genome code for a multitude of tiny proteins
Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity
The U.S. Food and Drug Administration (FDA) recently approved lecanemab and donanemab for the treatment of early symptomatic Alzheimer's disease (AD) after their phase III trials reached endpoints. These two anti-amyloid β monoclonal antibodies represent the latest promise of disease-modifying therapy (DMT) for AD, which undoubtedly reignites new hope for DMTs to combat the staggering financial and human costs of AD. However, in addition to these two successful antibodies, there have been...